Designing Longevity
Skip to main content
Brand-name GLP-1

Hims & Hers

Program terms need a fresh check

Edited by Designing Longevity Editorial · earlier profile checked May 1, 2026

Current program terms need a fresh check. Request a written care and medication quote. Earlier public-record dates are shown below.

Program terms need a fresh check. Ask Hims & Hers for a written quote covering care, medication, billing and cancellation. The dated public-record details remain below.

Reviews of individual programs

Program reviews cover their own costs, terms and support. The program-terms checklist applies to the named care program, not every service offered by this company.

Hims GLP-1 program review

Program costs and payment terms

Current program terms need a fresh check. Get a written price and billing quote directly before paying.

Membership
Current membership price needs a fresh check.
Insurance
Insurance terms need a fresh check; confirm directly before paying.

Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.

The full profile and rubric were last checked May 1, 2026. Current commercial terms above have their own check date; they do not refresh earlier ratings or clinical claims.

Read the earlier full profile and source record (May 1, 2026)

This record keeps its original check dates. The program-terms checklist above covers costs, billing and advertised support for the named care program.

Earlier editorial take

Look elsewhere if

  • Users who want labs ordered before a GLP-1 prescription

    Hims uses async intake without baseline labs before prescribing. If you want pre-treatment labs, this is not the model.

Our take

If you specifically want a brand-name from a public-company telehealth platform with mature compliance infrastructure, post-settlement Hims is a credible option, especially for the new oral pill. The honest counterweight: the September 2025 and the messy 2025 break with Novo Nordisk are both recent enough that we are docking the score below where a clean operator would land. at 3.0/5 with 28% one-star reviews is worse than Ro's, and the A+ does not fully offset that.

Pros

  • Public company (NYSE: HIMS) with SEC-grade financial disclosure
  • Accredited since 2018 with A+ rating, strongest in our cohort
  • Authorized distributor for Novo Nordisk , oral Wegovy pill, and post-settlement

Cons

  • Twin Sept 9, 2025 on - marketing claims
  • Messy 2025 break with Novo Nordisk over compounding before March 2026 settlement
  • 3.0/5 with 28% one-star reviews across roughly 8,000 reviews
  • No option for new patients post-settlement
  • Async-only consultations; no labs ordered before prescribing

Pricing

Current pricing needs a fresh check.

Turnaround

Same-day Rx after async intake

States served

All 50

Earlier full review checked

May 1, 2026

Earlier rubric breakdown

How the earlier rating was scored

Licensure

20% weight
3.0/5

License and enforcement records checked at the profile verification date.

Active 50-state telehealth licensure as a publicly-traded company with mature compliance infrastructure. Counterweight: twin dated September 9, 2025 directly to Hims & Hers Health Inc. (dba Hims and dba Hers) cited false or misleading claims on marketing. Recency is the issue here, the warning letters are eight months old at capture date and weighed against the operating-license signal.

Evidence checked in the earlier review (4)

  • Hims & Hers Health, Inc. (NYSE: HIMS) operating entity

    Business filing

    Publicly-traded under ticker HIMS; SEC filings are public. Founded 2017, IPO via SPAC merger in January 2021.

    Checked May 1, 2026

  • FDA Warning Letter to Hims & Hers Health Inc. dba Hims (CMS #716567)

    Federal enforcement

    Dated September 9, 2025. FDA cited claims like "Same active ingredient as and " and "Clinically proven ingredients" as false or misleading under sections 502(a) and 502(bb) of the FD&C Act, because drugs are not FDA-approved and cannot be marketed as equivalent to the brand-name approved products.

    Checked May 1, 2026 · source

  • FDA Warning Letter to Hims & Hers Health Inc. dba Hers (CMS #716825)

    Federal enforcement

    Companion warning letter to the Hers brand, also dated September 9, 2025, on the same - marketing claims.

    Checked May 1, 2026 · source

  • Active 50-state licensure

    State licensure

    Hims operates in all 50 states via a network of licensed independent clinicians.

    Checked May 1, 2026

Accreditation

20% weight
4.0/5

Accreditation records checked at the profile verification date.

Accredited Business since February 22, 2018 with an A+ rating, the strongest BBB posture in our cohort. certification is inferred (Hims advertises on Google and Meta, which require it) but not independently confirmable on a public registry, since LegitScript does not publish a per-merchant directory.

Evidence checked in the earlier review (2)

  • BBB Accredited since February 22, 2018, A+ rating

    Accreditation

    Hims & Hers Inc. (San Francisco) is the -accredited entity. A+ is the strongest BBB rating in our cohort.

    Checked May 1, 2026 · source

  • LegitScript Healthcare Merchant Certification

    Accreditation

    Inferred from active Google and Meta advertising (which requires ), but LegitScript does not publish a public per-merchant directory we could confirm against.

    Checked May 1, 2026 · source

Transparency

20% weight
3.5/5

Published testing, sourcing, and formulation information.

As a publicly-traded company, Hims has stronger baseline disclosure than private competitors (SEC filings, earnings calls, audited financials).

Evidence checked in the earlier review (1)

  • Public-company SEC filings

    Financial transparency

    NYSE: HIMS. Quarterly 10-Qs and annual 10-K are public. This is unusual disclosure depth in our cohort.

    Checked May 1, 2026

Product quality

15% weight
3.5/5

Published testing, recall, and supply-chain information.

This earlier product-quality score has not been refreshed. The commercial update does not recheck manufacturing, sourcing or clinical care.

Evidence checked in the earlier review (3)

  • Branded GLP-1 supply via authorized distribution

    Sourcing

    injection, oral Wegovy pill, and dispensed through Novo Nordisk authorized distribution post March 2026 settlement.

    Checked May 1, 2026 · source

  • No FDA recalls on Hims-distributed branded GLP-1

    Recall history

    Checked May 1, 2026 · source

  • Prior compounded-marketing posture (now corrected)

    Vendor/marketing oversight

    Twin Sept 9, 2025 cited misleading marketing on then-current . The company has since wound down compounded advertising under the March 2026 settlement, but the warning letters are recent enough to weigh.

    Checked May 1, 2026 · source

Pricing

15% weight
3.0/5

Value within the category, no surprise fees, refund policy.

Current pricing needs a fresh check.

Customer service

10% weight
3.0/5

Refund policy, support quality, complaint history.

Mixed external review picture: rates A+ with accreditation since 2018 (strong), is 3.0/5 across roughly 8,000 reviews with 28% one-star (weak). The split is real and large enough to weigh down this score. Top recurring negatives across platforms: cancellation friction, surprise charges, async-only consultations with no labs ordered before prescribing.

Evidence checked in the earlier review (3)

  • BBB A+ rating, accredited since February 22, 2018

    Complaint history

    A+ is the strongest rating in our cohort. Long-tenured accreditation is itself a positive signal.

    Checked May 1, 2026 · source

  • Trustpilot rating: 3.0/5 across roughly 8,000 reviews

    External review

    40% 5-star, 28% 1-star at capture date. The bimodal distribution is itself a signal: a large slice of users is genuinely unhappy.

    Checked May 1, 2026 · source

  • Async-only consultations, no labs before prescribing

    Care model

    Telehealth-typical: synchronous video is not standard, and labs are not ordered before issuing a prescription.

    Checked May 1, 2026

Public reviews

What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.

Trustpilot

3.0/5 across roughly 8,000 reviews. Distribution is bimodal: 40% 5-star, 28% 1-star. Negatives concentrate on cancellation friction, surprise charges, and difficulty unsubscribing. Positives concentrate on convenience and visible results.

Captured May 1, 2026Source

Better Business Bureau

Accredited since February 22, 2018; current rating A+. The complaint themes mirror (cancellation, refund processing, unauthorized charges) but the company has been responsive enough to maintain A+ accreditation, which is the strongest BBB posture in our cohort.

Captured May 1, 2026Source

ConsumerAffairs

Recurring negative themes: misleading sign-up flow, automatic refill structure, prepaid annual billing. The pattern matches rather than the complaint resolution view.

Captured May 1, 2026Source

Regulatory & legal history

FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.

  1. FDA Warning LetterSeptember 9, 2025

    FDA issued warning letter (CMS #716567) to Hims & Hers Health Inc. dba Hims, citing claims like "Same active ingredient as and " and "Clinically proven ingredients" on the - product page as false or misleading under sections 502(a) and 502(bb) of the FD&C Act. Compounded drugs are not FDA-approved and cannot be marketed as equivalent to brand-name approved products. Hims was given 15 working days to respond.

    Source
  2. FDA Warning LetterSeptember 9, 2025

    Companion (CMS #716825) to Hims & Hers Health Inc. dba Hers, on the same - marketing claims. Issued the same day.

    Source
  3. Lawsuit FiledJune 22, 2025

    Novo Nordisk terminated its April 2025 collaboration with Hims & Hers, citing concerns about Hims's continued mass compounding of and what Novo described as deceptive marketing of copycats of .

    Source
  4. SettlementMarch 9, 2026

    Novo Nordisk and Hims & Hers reached a settlement: Novo dropped its lawsuit and Hims became an authorized seller of (injection and oral pill) and . As part of the deal, Hims agreed to stop advertising medications. This resolved the prior 2025 dispute and reset the commercial relationship.

    Source

What to expect

  1. 1

    Pharmacy fulfillment via authorized distribution

    3-7 days

    Approved for branded or routes through authorized pharmacy distribution. Cold-chain shipping for injections; the oral Wegovy pill ships standard.

Accreditations

State pharmacy/clinic license

Verified · May 1, 2026

LegitScript Certified

Unverified · May 1, 2026 · source

Frequently asked

What does Hims & Hers charge for membership?

Current membership price needs a fresh check.

Does Hims & Hers accept insurance?

Insurance terms need a fresh check; confirm directly before paying.

Is Hims BBB-accredited?

Yes. Hims & Hers Inc. (San Francisco) has been Accredited since February 22, 2018 with an A+ rating, the strongest BBB posture in our cohort. The profile is at https://www.bbb.org/us/ca/san-francisco/profile/health-and-medical-products/hims-hers-inc-1116-880029. Long-tenured A+ accreditation is itself a positive signal even though reviews are weaker.

Why is the Trustpilot score so much lower than the BBB rating?

is 3.0/5 across roughly 8,000 reviews with 28% one-star ratings, while is A+ accredited since 2018. The two platforms measure different things. BBB ratings reflect complaint resolution behavior over time, where Hims is responsive enough to maintain A+. Trustpilot reflects what individual customers post, where the most upset users dominate. Both are real signals; we weigh them both. The recurring Trustpilot negatives match BBB complaint themes (cancellation friction, surprise charges).

Update history

Every meaningful change to this profile, with a date stamp. We don't silently re-score.

  1. May 1, 2026

    Initial published profile. Sources HEAD-checked at publish time. Score (3.4) reflects the trade-off between strong baseline signals (public-company disclosure, A+ since 2018, post-settlement branded-only supply chain) and meaningful negatives (twin Sept 2025, 3.0/5 with 28% one-star, recurring billing-friction complaints). The March 2026 Novo settlement is recent enough that we may revisit the score in a future review window.

Edited by Designing Longevity Editorial. Earlier profile checked May 1, 2026.

Spot something out of date or wrong? Let us know and we'll re-check.

Back to all providers